Teleflex Incorporated (NYSE: TFX) announced its second quarter 2026 financial results, surpassing analyst expectations for earnings per share. The medical technology firm reported adjusted diluted earnings per share of $1.76, exceeding the consensus estimate of $1.28 by $0.48. This marks a significant beat for the company, which also saw its revenue from continuing operations reach $570.3 million, higher than the $559.6 million anticipated by analysts.
Despite strong earnings, Teleflex lowered its full-year 2026 revenue growth outlook to a range of 3.5% to 4.5% on a pro forma adjusted constant currency basis. This adjustment is primarily due to longer-than-expected integration timelines for its acquired Vascular Intervention business. However, the company raised its full-year 2026 adjusted diluted earnings per share guidance to $6.90-$7.20, up from the previous forecast of $6.25-$6.55.
In line with its commitment to returning capital to shareholders, Teleflex completed its approximately $1.5 billion sale of its medical OEM business and plans to commence an accelerated share repurchase program of $250 million, effective August 7, 2026. The company also recently refinanced its credit agreement, securing a $1 billion revolving credit facility and a $500 million term A-1 loan facility. CEO Jason Weidman highlighted the company's strong performance in its Vascular and Surgical businesses, while emphasizing the strategic importance of the OEM divestiture in strengthening the company's balance sheet and focus on core operations.
